In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2026–2030: Forecasting Business Opportunities Ahead
Uncover key drivers, emerging technologies, and competitive movements shaping the in vitro diagnostic (ivd) in cardiology and neurology market from 2026–2035 with trusted insights from The Business Research Company
What level of growth is expected in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market between 2026 and 2030?
The market for in vitro diagnostics (ivd) in cardiology and neurology has demonstrated substantial growth over recent years. This market is projected to expand from $17.22 billion in 2025 to $18.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.7%. The historical growth can be linked to several factors, including the rising prevalence of cardiovascular diseases, an increase in neurological disorders, the expansion of hospital diagnostic infrastructure, progress in immunoassay technologies, and greater clinical awareness regarding early diagnosis.
The in vitro diagnostic (ivd) in cardiology and neurology market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $25.18 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.7%. This expansion over the forecast period is largely attributed to factors such as the global aging population, an increasing need for personalized diagnostics, the growth of point-of-care testing facilities, rising healthcare expenditure in emerging markets, and the increasing adoption of molecular diagnostics. Prominent trends for the forecast period include a growing demand for early disease detection, wider use of point-of-care cardiac and neuro tests, the proliferation of biomarker-based diagnostics, a stronger emphasis on preventive and predictive testing, and the integration of multi-parameter diagnostic panels.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp
Which Drivers Are Expected To Impact The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market During The Forecast Period?
The expansion of personalized medicine is projected to stimulate the growth of the in vitro diagnostic (IVD) in cardiology and neurology market moving forward. Personalized medicine defines a medical strategy that customizes healthcare choices, practices, interventions, and treatments to the distinct characteristics of each patient. This medical approach is growing due to advancements in genomics, an enhanced understanding of disease mechanisms, patient demand for tailored therapies, and regulatory support, among other aspects. In vitro diagnostic (IVD) tests in cardiology and neurology aid personalized medicine by delivering essential details regarding an individual’s genetic composition and disease status, thereby guiding customized treatment plans for improved effectiveness and reduced risks. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022, with the 2023 approvals additionally including seven oncology therapies and three treatments addressing various other conditions. Thus, the increasing number of personalized medicines is fueling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.
How Is The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Divided Into Segments?
The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users
Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services
Which Market Trends Are Opening Growth Opportunities In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
Leading companies operating within the in vitro diagnostic (IVD) in cardiology and neurology market are engaged in creating AI-enabled integrated epigenetic engines designed for the early identification of diseases and risk assessment. These AI-enabled integrated epigenetic engines leverage machine-learning models and advanced biomarker analysis methods to improve the sensitivity and accuracy in diagnosing and overseeing cardiovascular diseases, thus addressing key elements of disease progression. For instance, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, introduced PrecisionCHD, an AI-based blood test, intended for the prompt detection of coronary heart disease (CHD). Utilizing the company’s integrated epigenetic-genetic engine, this test evaluates CHD risk and aims to prevent and detect the most common type of cardiovascular disease. The new test combines epigenetic and genetic biomarkers with machine-learning algorithms, offering over 75% sensitivity for both men and women. It connects a patient’s biomarker profile to modifiable risk factors, which are major contributors to CHD, including smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD represents a non-invasive option compared to exercise stress tests or angiograms, with blood samples drawn either in-office or at home.
Which Major Firms Are Strengthening Their Position In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp
Browse Through More Reports Similar to the Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market 2026, By The Business Research Company
Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026
In Vitro Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report
In Vitro Diagnostics Ivd Quality Control Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
